Skip to main content
SpringerLink
Log in
Book cover

Hepatocellular Carcinoma pp 305–329Cite as

Aspects of Hepatocellular Tumor Pathology

  • Chapter
  • First Online:

  • 2059 Accesses

Part of the book series: Current Clinical Oncology ((CCO))

Abstract

The pathologic analysis of hepatocellular carcinoma (HCC) is updated almost daily by advances at the molecular level. However, contextual assessment of these advances is dependent upon the proper diagnosis of HCC and its distinction from other malignant or benign tumors that may involve the liver. Tissue diagnosis is not necessary in every patient, but problematic tumors require pathologic examination for definitive diagnosis; in addition, tissue samples provide a valuable resource for directed studies that may provide prognostic or therapeutic (theranostic) information. In the United States, pathologic evaluation of the explanted liver in transplant recipients previously diagnosed with HCC is mandated by the OPTN/UNOS as a quality control measure to monitor the performance of transplant programs.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   89.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD   169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

References

  1. Bioulac-Sage P, Balabaud C, Bedossa P, Scoazec JY, Chiche L, Dhillon AP, et al. Pathological diagnosis of liver cell adenoma and focal nodular hyperplasia: Bordeaux update. J Hepatol. 2007;46(3):521–7.

    Article  CAS  PubMed  Google Scholar 

  2. Rebouissou S, Bioulac-Sage P, Zucman-Rossi J. Molecular pathogenesis of focal nodular hyperplasia and hepatocellular adenoma. J Hepatol. 2008;48(1):163–70.

    Article  CAS  PubMed  Google Scholar 

  3. Zucman Rossi J, Jeannot E, Nhieu JTV, Scoazec J-Y, Guettier C, Rebouissou S, et al. Genotype-phenotype correlation in hepatocellular adenoma: new classification and relationship with HCC. Hepatology. 2006;43(3):515–24.

    Google Scholar 

  4. Rifai K, Mix H, Krusche S, Potthoff A, Manns MP, Gebel MJ. No evidence of substantial growth progression or complications of large focal nodular hyperplasia during pregnancy. Scand J Gastroenterol. 2013;48(1):88–92.

    Article  PubMed  Google Scholar 

  5. Sato A, Rai T, Takahashi A, Saito H, Takagi T, Shibukawa G, et al. A case of rapidly expanding and increasing focal nodular hyperplasia. Fukushima J Med Sci. 2006;52(2):149–55.

    Article  PubMed  Google Scholar 

  6. Buscarini E, Danesino C, Plauchu H, de Fazio C, Olivieri C, Brambilla G, et al. High prevalence of hepatic focal nodular hyperplasia in subjects with hereditary hemorrhagic telangiectasia. Ultrasound Med Biol. 2004;30(9):1089–97.

    Article  PubMed  Google Scholar 

  7. Pupulim LF, Vullierme M-P, Paradis V, Valla D, Terraz S, Vilgrain V. Congenital portosystemic shunts associated with liver tumours. Clin Radiol. 2013;68(7):e362–9.

    Google Scholar 

  8. Joyner BL, Levin TL, Goyal RK, Newman B. Focal nodular hyperplasia of the liver: a sequela of tumor therapy. Pediatr Radiol. 2005;35(12):1234–9.

    Article  PubMed  Google Scholar 

  9. Masetti R, Colecchia A, Rondelli R, Martoni A, Vendemini F, Biagi C, et al. Benign hepatic nodular lesions after treatment for childhood cancer. J Pediatr Gastroenterol Nutr. 2013;56(2):151–5.

    Article  CAS  PubMed  Google Scholar 

  10. Ronot M, Vilgrain V. Imaging of benign hepatocellular lesions: current concepts and recent updates. Clin Res Hepatol Gastroenterol. 2014;38(6):681–8.

    Article  PubMed  Google Scholar 

  11. Rahili A, Cai J, Trastour C, Juwid A, Benchimol D, Zheng M, et al. Spontaneous rupture and hemorrhage of hepatic focal nodular hyperplasia in lobus caudatus. J Hepatobiliary Pancreat Surg. 2005;12(2):138–42.

    Google Scholar 

  12. Khan MR, Saleem T, Haq TU, Aftab K. Atypical focal nodular hyperplasia of the liver. Hepatobiliary Pancreat Dis Int. 2011;10(1):104–6.

    Article  PubMed  Google Scholar 

  13. Petsas T, Tsamandas A, Tsota I, Karavias D, Karatza C, Vassiliou V, et al. A case of hepatocellular carcinoma arising within large focal nodular hyperplasia with review of the literature. World J Gastroenterol. 2006;12(40):6567–71.

    Google Scholar 

  14. Yamamoto M, Ariizumi S, Yoshitoshi K, Saito A, Nakano M, Takasaki K. Hepatocellular carcinoma with a central scar and a scalloped tumor margin resembling focal nodular hyperplasia in macroscopic appearance. J Surg Oncol. 2006;94(7):587–91.

    Google Scholar 

  15. Shen Y-H, Fan J, Wu Z-Q, Ma Z-C, Zhou X-D, Zhou J, et al. Focal nodular hyperplasia of the liver in 86 patients. Hepatobiliary Pancreat Dis Int. 2007;6(1):52–7.

    PubMed  Google Scholar 

  16. Shih A, Lauwers GY, Balabaud C, Bioulac-Sage P, Misdraji J. Simultaneous occurrence of focal nodular hyperplasia and HNF1A-inactivated hepatocellular adenoma: a collision tumor simulating a composite FNH-HCA. Am J Surg Pathol. 2015;39(9):1296–300.

    Article  PubMed  Google Scholar 

  17. Imkie M, Myers SA, Li Y, Fan F, Bennett TL, Forster J, et al. Fibrolamellar hepatocellular carcinoma arising in a background of focal nodular hyperplasia: a report of 2 cases. J Reprod Med. 2005;50(8):633–7.

    PubMed  Google Scholar 

  18. Sotiropoulos GC, Bockhorn M, Molmenti EP, Fouzas I, Broelsch CE, Lang H. Hepatocellular carcinoma as a coincidental finding in a patient undergoing surgery for focal nodular hyperplasia. Liver Int. 2008;28(4):578–9.

    Google Scholar 

  19. Joseph NM, Ferrell LD, Jain D, Torbenson MS, Wu T-T, Yeh MM, et al. Diagnostic utility and limitations of glutamine synthetase and serum amyloid-associated protein immunohistochemistry in the distinction of focal nodular hyperplasia and inflammatory hepatocellular adenoma. Mod Pathol. 2014;27(1):62–72.

    Article  CAS  PubMed  Google Scholar 

  20. Dhingra S, Fiel MI. Update on the new classification of hepatic adenomas: clinical, molecular, and pathologic characteristics. Arch Pathol Lab Med. 2014;138(8):1090–7.

    Google Scholar 

  21. Rooks JB, Ory HW, Ishak KG, Strauss LT, Greenspan JR, Hill AP, et al. Epidemiology of hepatocellular adenoma: the role of oral contraceptive use. JAMA. 1979;242(7):644–8.

    Article  CAS  PubMed  Google Scholar 

  22. Espat J, Chamberlain RS, Sklar C, Blumgart LH. Hepatic adenoma associated with recombinant human growth hormone therapy in a patient with Turner’s syndrome. Dig Surg. 2000;17(6):640–3.

    Article  CAS  PubMed  Google Scholar 

  23. Lautz TB, Finegold MJ, Chin AC, Superina RA. Giant hepatic adenoma with atypical features in a patient on oxcarbazepine therapy. J Pediatr Surg. 2008;43(4):751–4.

    Article  CAS  PubMed  Google Scholar 

  24. Lizardi-Cervera J, Cuéllar-Gamboa L, Motola-Kuba D. Focal nodular hyperplasia and hepatic adenoma: a review. Ann Hepatol. 2006;5(3):206–11.

    PubMed  Google Scholar 

  25. Deneve JL, Pawlik TM, Cunningham S, Clary B, Reddy S, Scoggins CR, et al. Liver cell adenoma: a multicenter analysis of risk factors for rupture and malignancy. Ann Surg Oncol. 2009;16(3):640–8.

    Google Scholar 

  26. Bieze M, Phoa SSKS, Verheij J, van Lienden KP, van Gulik TM. Risk factors for bleeding in hepatocellular adenoma. Br J Surg. 2014;101(7):847–55.

    Google Scholar 

  27. Aseni P, Sansalone CV, Sammartino C, Benedetto FD, Carrafiello G, Giacomoni A, et al. Rapid disappearance of hepatic adenoma after contraceptive withdrawal. J Clin Gastroenterol. 2001;33(3):234–6.

    Article  CAS  PubMed  Google Scholar 

  28. Stoot JHMB, Coelen RJS, De Jong MC, Dejong CHC. Malignant transformation of hepatocellular adenomas into hepatocellular carcinomas: a systematic review including more than 1600 adenoma cases. 2010;12(8):509–22.

    Google Scholar 

  29. Chevallier P, Peten EP, Baldini E, Gugenheim J. Pedunculated hepatic adenoma: sonographic and MR imaging features. AJR Am J Roentgenol. 1999;172(4):1146–7.

    Google Scholar 

  30. Frulio N, Chiche L, Bioulac Sage P, Balabaud C. Hepatocellular adenomatosis: what should the term stand for! Clin Res Hepatol Gastroenterol. 2014;38(2):132–6.

    Google Scholar 

  31. Iijima H, Moriwaki Y, Yamamoto T, Takahashi S, Nishigami T, Hada T. Spontaneous regression of hepatic adenoma in a patient with glycogen storage disease type I after hemodialysis: ultrasonographic and CT findings. Intern Med. 2001;40(9):891–5.

    Article  CAS  PubMed  Google Scholar 

  32. Hung CH, Changchien CS, Lu SN, Eng HL, Wang JH, Lee CM, et al. Sonographic features of hepatic adenomas with pathologic correlation. Abdom Imaging. 2001;26(5):500–6.

    Article  CAS  PubMed  Google Scholar 

  33. Palmer PE, Christopherson WM, Wolfe HJ. Alpha1-antitrypsin, protein marker in oral contraceptive-associated hepatic tumors. Am J Clin Pathol. 1977;68(6):736–9.

    Article  CAS  PubMed  Google Scholar 

  34. Poe R, Snover DC. Adenomas in glycogen storage disease type 1. Two cases with unusual histologic features. Am J Surg Pathol. 1988;12(6):477–83.

    Article  CAS  PubMed  Google Scholar 

  35. Heffelfinger S, Irani DR, Finegold MJ. “Alcoholic hepatitis” in a hepatic adenoma. Hum Pathol. 1987;18(7):751–4.

    Article  CAS  PubMed  Google Scholar 

  36. Tao LC. Oral contraceptive-associated liver cell adenoma and hepatocellular carcinoma. Cytomorphology and mechanism of malignant transformation. Cancer. 1991;68(2):341–7.

    Article  CAS  PubMed  Google Scholar 

  37. Salaria SN, Graham RP, Aishima S, Mounajjed T, Yeh MM, Torbenson MS. Primary hepatic tumors with myxoid change: morphologically unique hepatic adenomas and hepatocellular carcinomas. Am J Surg Pathol. 2015;39(3):318–24.

    Article  PubMed  Google Scholar 

  38. Micchelli STL, Vivekanandan P, Boitnott JK, Pawlik TM, Choti MA, Torbenson M. Malignant transformation of hepatic adenomas. Mod Pathol. 2008;21(4):491–7.

    Article  CAS  PubMed  Google Scholar 

  39. Bioulac Sage P, Laumonier H, Couchy G, Le Bail B, Sa Cunha A, Rullier A, et al. Hepatocellular adenoma management and phenotypic classification: the Bordeaux experience. Hepatology. 2009;50(2):481–9.

    Google Scholar 

  40. Bioulac Sage P, Rebouissou S, Thomas C, Blanc JF, Saric J, Sa Cunha A, et al. Hepatocellular adenoma subtype classification using molecular markers and immunohistochemistry. Hepatology. 2007;46(3):740–8.

    Google Scholar 

  41. Bioulac Sage P, Balabaud C, Zucman Rossi J. Subtype classification of hepatocellular adenoma. Dig Surg. 2010;27(1):39–45.

    Google Scholar 

  42. Nault JC, Fabre M, Couchy G, Pilati C, Jeannot E, Tran Van Nhieu J, et al. GNAS-activating mutations define a rare subgroup of inflammatory liver tumors characterized by STAT3 activation. J Hepatol. 2012;56(1):184–91.

    Article  CAS  PubMed  Google Scholar 

  43. Pilati C, Letouzé E, Nault JC, Imbeaud S, Boulai A, Calderaro J, et al. Genomic profiling of hepatocellular adenomas reveals recurrent FRK-activating mutations and the mechanisms of malignant transformation. Cancer Cell. 2014;25(4):428–41.

    Article  CAS  PubMed  Google Scholar 

  44. Dokmak S, Paradis V, Vilgrain V, Sauvanet A, Farges O, Valla D, et al. A Single-center surgical experience of 122 patients with single and multiple hepatocellular adenomas. Gastroenterology. 2009;137(5):1698–705.

    Article  PubMed  Google Scholar 

  45. Castain C, Sempoux C, Brunt EM, Causse O, Heitzmann A, Hernandez-Prera JC, et al. Coexistence of inflammatory hepatocellular adenomas with HNF1α-inactivated adenomas: is there an association? Histopathology. 2014;64(6):890–5.

    Article  PubMed  Google Scholar 

  46. Zucman Rossi J, Villanueva A, Nault JC, Llovet JM. Genetic landscape and biomarkers of hepatocellular carcinoma. Gastroenterology. 2015;149(5):1226–1239.e4.

    Google Scholar 

  47. The International Consensus Group for Hepatocellular Neoplasia. Pathologic diagnosis of early hepatocellular carcinoma: a report of the international consensus group for hepatocellular neoplasia. Hepatology. 2009;49(2):658–64.

    Google Scholar 

  48. Di Tommaso L, Franchi G, Park YN, Fiamengo B, Destro A, Morenghi E, et al. Diagnostic value of HSP70, glypican 3, and glutamine synthetase in hepatocellular nodules in cirrhosis. Hepatology. 2007;45(3):725–34.

    Google Scholar 

  49. Centers for Disease Control, Prevention. Hepatocellular Carcinoma—United States, 2001–2006 [Internet]. [cited 14 Nov 2015]. Available from: http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5917a3.htm.

  50. Centers for Disease Control. Surveillance for Viral Hepatitis—United States, 2013 [Internet]. [cited 14 Nov 2015]. Available from: http://www.cdc.gov/hepatitis/statistics/2013surveillance/index.htm#tabs-801919-8.

  51. Wei Q, Guo P, Mu K, Zhang Y, Zhao W, Huai W, et al. Estrogen suppresses hepatocellular carcinoma cells through ERβ-mediated upregulation of the NLRP3 inflammasome. Lab Invest. 2015;95(7):804–16.

    Article  CAS  PubMed  Google Scholar 

  52. Leung C, Yeoh SW, Patrick D, Ket S, Marion K, Gow P, et al. Characteristics of hepatocellular carcinoma in cirrhotic and non-cirrhotic non-alcoholic fatty liver disease. World J Gastroenterol. 2015;21(4):1189–96.

    Article  PubMed  PubMed Central  Google Scholar 

  53. Trevisani F, Caraceni P, Bernardi M, D’Intino PE, Arienti V, Amorati P, et al. Gross pathologic types of hepatocellular carcinoma in Italian patients. relationship with demographic, environmental, and clinical factors. Cancer. 1993;72(5):1557–63.

    Article  CAS  PubMed  Google Scholar 

  54. Eggel H. Uber das primare carcinom der leber. Beitr Pathol Anat. 1901;30:506.

    Google Scholar 

  55. Shimada M, Rikimaru T, Hamatsu T, Yamashita Y, Terashi T, Taguchi K, et al. The role of macroscopic classification in nodular-type hepatocellular carcinoma. Am J Surg. 2001;182(2):177–82.

    Article  CAS  PubMed  Google Scholar 

  56. Stroffolini T, Andreone P, Andriulli A, Ascione A, Craxì A, Chiaramonte M, et al. Gross pathologic types of hepatocellular carcinoma in Italy. Oncology. 1999;56(3):189–92.

    Article  CAS  PubMed  Google Scholar 

  57. Horie Y, Katoh S, Yoshida H, Imaoka T, Suou T, Hirayama C. Pedunculated hepatocellular carcinoma. Report of three cases and review of literature. Cancer. 1983;51(4):746–51.

    Article  CAS  PubMed  Google Scholar 

  58. Horie Y, Shigoku A, Tanaka H, Tomie Y, Maeda N, Hoshino U, et al. Prognosis for pedunculated hepatocellular carcinoma. Oncology. 1999;57(1):23–8.

    Article  CAS  PubMed  Google Scholar 

  59. Okuda K. Hepatocellular carcinoma. J Hepatol. 2000;32(1 Suppl):225–37.

    Article  CAS  PubMed  Google Scholar 

  60. Albacete RA, Matthews MJ, Saini N. Portal vein thromboses in malignant hepatoma. Ann Intern Med. 1967;67(2):337–48.

    Article  CAS  PubMed  Google Scholar 

  61. Zhou XD, Tang Z-Y, Yang BH, Lin ZY, Ma ZC, Ye SL, et al. Experience of 1000 patients who underwent hepatectomy for small hepatocellular carcinoma. Cancer. 2001;91(8):1479–86.

    Article  CAS  PubMed  Google Scholar 

  62. Ohkubo T, Yamamoto J, Sugawara Y, Shimada K, Yamasaki S, Makuuchi M, et al. Surgical results for hepatocellular carcinoma with macroscopic portal vein tumor thrombosis. J Am Coll Surg. 2000;191(6):657–60.

    Article  CAS  PubMed  Google Scholar 

  63. Kojiro M, Kawabata K, Kawano Y, Shirai F, Takemoto N, Nakashima T. Hepatocellular carcinoma presenting as intrabile duct tumor growth: a clinicopathologic study of 24 cases. Cancer. 1982;49(10):2144–7.

    Article  CAS  PubMed  Google Scholar 

  64. Kojiro M, Nakahara H, Sugihara S, Murakami T, Nakashima T, Kawasaki H. Hepatocellular carcinoma with intra-atrial tumor growth. A clinicopathologic study of 18 autopsy cases. Arch Pathol Lab Med. 1984;108(12):989–92.

    CAS  PubMed  Google Scholar 

  65. Nakashima T, Okuda K, Kojiro M, Jimi A, Yamaguchi R, Sakamoto K, et al. Pathology of hepatocellular carcinoma in Japan. 232 consecutive cases autopsied in ten years. Cancer. 1983;51(5):863–77.

    Article  CAS  PubMed  Google Scholar 

  66. Tantawi B, Cherqui D, Tran van Nhieu J, Kracht M, Fagniez PL. Surgery for biliary obstruction by tumour thrombus in primary liver cancer. Br J Surg. 1996;83(11):1522–5.

    Article  CAS  PubMed  Google Scholar 

  67. He J, Shi J, Fu X, Mao L, Zhou T, Qiu Y, et al. The clinicopathologic and prognostic significance of gross classification on solitary hepatocellular carcinoma after hepatectomy. Medicine. 2015;94(32):e1331.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  68. Kang TW, Lim HK, Lee MW, Kim Y-S, Rhim H, Lee WJ, et al. Aggressive intrasegmental recurrence of hepatocellular carcinoma after radiofrequency ablation: risk factors and clinical significance. Radiology. 2015;276(1):274–85.

    Article  PubMed  Google Scholar 

  69. Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti III A, editors. AJCC cancer staging manual. 7th ed. Berlin: Springer; 2010. pp. 191–9.

    Google Scholar 

  70. OPTN. Organ procurement and transplantation network policies [Internet]. [cited 14 Nov 2015]. Available from: http://optn.transplant.hrsa.gov/media/1200/optn_policies.pdf#nameddest=Policy_03.

  71. Mazzaferro V, Regalia E, Doci R, Andreola S, Pulvirenti A, Bozzetti F, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med. 1996;334(11):693–9.

    Article  CAS  PubMed  Google Scholar 

  72. Llovet JM, Brú C, Bruix J. Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin Liver Dis. 1999;19(3):329–38.

    Google Scholar 

  73. Prospective validation of the CLIP score: a new prognostic system for patients with cirrhosis and hepatocellular carcinoma. The Cancer of the Liver Italian Program (CLIP) investigators. Hepatology. 2000;31(4):840–5.

    Google Scholar 

  74. Yau T, Tang VYF, Yao T-J, Fan S-T, Lo C-M, Poon RTP. Development of Hong Kong liver cancer staging system with treatment stratification for patients with hepatocellular carcinoma. Gastroenterology. 2014;146(7):1691–3.

    Article  PubMed  Google Scholar 

  75. Sherman M. Staging for hepatocellular carcinoma: complex and confusing. Gastroenterology. 2014;146(7):1599–602.

    Article  PubMed  Google Scholar 

  76. Komatsu T, Kondo Y, Yamamoto Y, Isono K. Hepatocellular carcinoma presenting well differentiated, normotrabecular patterns in peripheral or metastatic loci. Analysis of 103 resected cases. Acta Pathol Jpn. 1990;40(12):887–93.

    CAS  PubMed  Google Scholar 

  77. Nakashima T, Kojiro M. Pathologic characteristics of hepatocellular carcinoma. Semin Liver Dis. 1986;6(3):259–66.

    Google Scholar 

  78. Li Y, Ma X, Zhang J, Liu X, Liu L. Prognostic value of microvessel density in hepatocellular carcinoma patients: a meta-analysis. Int J Biol Markers. 2014;29(3):e279–87.

    Article  PubMed  Google Scholar 

  79. Kondo Y, Nakajima T. Pseudoglandular hepatocellular carcinoma. A morphogenetic study. Cancer. 1987;60(5):1032–7.

    Article  CAS  PubMed  Google Scholar 

  80. Lauwers GY, Terris B, Balis UJ, Batts KP, Regimbeau J-M, Chang Y, et al. Prognostic histologic indicators of curatively resected hepatocellular carcinomas: a multi-institutional analysis of 425 patients with definition of a histologic prognostic index. Am J Surg Pathol. 2002;26(1):25–34.

    Article  PubMed  Google Scholar 

  81. Hoshimoto S, Morise Z, Suzuki K, Tanahashi Y, Ikeda M, Kagawa T, et al. Hepatocellular carcinoma with extensive peliotic change. J Hepatobiliary Pancreat Surg. 2009;16(4):566–70.

    Article  PubMed  Google Scholar 

  82. Nomura Y, Nakashima O, Kumabe T, Akiba J, Ogasawara S, Kage M, et al. Clinicopathologic analysis of the simple nodular type of well-differentiated hepatocellular carcinoma with extensive peliotic change. J Gastroenterol Hepatol. 2014;29(7):1494–9.

    Article  PubMed  Google Scholar 

  83. Shibahara J, Ando S, Sakamoto Y, Kokudo N, Fukayama M. Hepatocellular carcinoma with steatohepatitic features: a clinicopathological study of Japanese patients. Histopathology. 2014;64(7):951–62.

    Article  PubMed  Google Scholar 

  84. Moon WS, Yu HC, Chung MJ, Kang MJ, Lee DG. Pale bodies in hepatocellular carcinoma. J Korean Med Sci. 2000;15(5):516–20.

    Google Scholar 

  85. Nakanuma Y, Kono N, Ohta G, Shirasaki S, Takeshita H, Watanabe K, et al. Pale eosinophilic inclusions simulating ground-glass appearance of cells of hepatocellular carcinoma. Acta Pathol Jpn. 1982;32(1):71–81.

    CAS  PubMed  Google Scholar 

  86. Stromeyer FW, Ishak KG, Gerber MA, Mathew T. Ground-glass cells in hepatocellular carcinoma. Am J Clin Pathol. 1980;74(3):254–8.

    Article  CAS  PubMed  Google Scholar 

  87. Stumptner C, Heid H, Fuchsbichler A, Hauser H, Mischinger HJ, Zatloukal K, et al. Analysis of intracytoplasmic hyaline bodies in a hepatocellular carcinoma: demonstration of p62 as major constituent. Am J Pathol. 1999;154(6):1701–10.

    Google Scholar 

  88. Kessler SM, Laggai S, Barghash A, Schultheiss CS, Lederer E, Artl M, et al. IMP2/p62 induces genomic instability and an aggressive hepatocellular carcinoma phenotype. Cell Death Dis Nat. 2015;6(10):e1894.

    Article  CAS  Google Scholar 

  89. Jensen K, Gluud C. The Mallory body: morphological, clinical and experimental studies (part 1 of a literature survey). Hepatology. 1994;20(4 Pt 1):1061–77.

    Article  CAS  PubMed  Google Scholar 

  90. Jensen K, Gluud C. The Mallory body: theories on development and pathological significance (part 2 of a literature survey). Hepatology. 1994;20(5):1330–42.

    Article  CAS  PubMed  Google Scholar 

  91. Dominguez-Malagón H, Gaytan-Graham S. Hepatocellular carcinoma: an update. Ultrastruct Pathol. 2001;25(6):497–516.

    Article  PubMed  Google Scholar 

  92. Liu K, He X, Lei X-Z, Zhao L-S, Tang H, Liu L, et al. Pathomorphological study on location and distribution of Kupffer cells in hepatocellular carcinoma. World J Gastroenterol. 2003;9(9):1946–9.

    Article  PubMed  PubMed Central  Google Scholar 

  93. Tsujimoto T, Kuriyama S, Yamazaki M, Nakatani Y, Okuda H, Yoshiji H, et al. Augmented hepatocellular carcinoma progression and depressed kupffer cell activity in rat cirrhotic livers. Int J Oncol. 2001;18(1):41–7.

    CAS  PubMed  Google Scholar 

  94. Ishizaki M, Ashida K, Higashi T, Nakatsukasa H, Kaneyoshi T, Fujiwara K, et al. The formation of capsule and septum in human hepatocellular carcinoma. Virchows Arch. 2001;438(6):574–80.

    Article  CAS  PubMed  Google Scholar 

  95. Okuda K, Musha H, Nakajima Y, Kubo Y, Shimokawa Y, Nagasaki Y, et al. Clinicopathologic features of encapsulated hepatocellular carcinoma: a study of 26 cases. Cancer. 1977;40(3):1240–5.

    Article  CAS  PubMed  Google Scholar 

  96. Torimura T, Ueno T, Inuzuka S, Tanaka M, Abe H, Tanikawa K. Mechanism of fibrous capsule formation surrounding hepatocellular carcinoma. Immunohistochemical study. Arch Pathol Lab Med. 1991;115(4):365–71.

    CAS  PubMed  Google Scholar 

  97. Kim JM, Kwon CHD, Joh J-W, Sinn DH, Park JB, Lee JH, et al. Incidental microscopic bile duct tumor thrombi in hepatocellular carcinoma after curative hepatectomy: a matched study. Medicine. 2015;94(6):e450.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  98. Edmondson HA, Steiner PE. Primary carcinoma of the liver: a study of 100 cases among 48,900 necropsies. Cancer. 1954;7(3):462–503.

    Article  CAS  PubMed  Google Scholar 

  99. Ishak KG, Goodman ZD, Stocker JT, editors. Tumors of the liver and intrahepatic bile ducts. Armed Forces Institute of Pathology: American Registry of Pathology; 2001.

    Google Scholar 

  100. Tannapfel A, Wasner M, Krause K, Geissler F, Katalinic A, Hauss J, et al. Expression of p73 and its relation to histopathology and prognosis in hepatocellular carcinoma. J Natl Cancer Inst. 1999;91(13):1154–8.

    Article  CAS  PubMed  Google Scholar 

  101. Zhou L, Rui J-A, Wang S-B, Chen S-G, Qu Q. Clinicopathological predictors of poor survival and recurrence after curative resection in hepatocellular carcinoma without portal vein tumor thrombosis. Pathol Oncol Res. 2015;21(1):131–8.

    Google Scholar 

  102. Minervini MI, Demetris AJ, Lee RG, Carr BI, Madariaga J, Nalesnik MA. Utilization of hepatocyte-specific antibody in the immunocytochemical evaluation of liver tumors. Mod Pathol. 1997;10(7):686–92.

    CAS  PubMed  Google Scholar 

  103. Borscheri N, Roessner A, Röcken C. Canalicular immunostaining of neprilysin (CD10) as a diagnostic marker for hepatocellular carcinomas. Am J Surg Pathol. 2001;25(10):1297–303.

    Article  CAS  PubMed  Google Scholar 

  104. Xiao SY, Wang HL, Hart J, Fleming D, Beard MR. cDNA arrays and immunohistochemistry identification of CD10/CALLA expression in hepatocellular carcinoma. Am J Pathol. 2001;159(4):1415–21.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  105. Pittman ME, Brunt EM. Anatomic pathology of hepatocellular carcinoma: histopathology using classic and new diagnostic tools. Clin Liver Dis. 2015;19(2):239–59.

    Article  PubMed  Google Scholar 

  106. Wennerberg AE, Nalesnik MA, Coleman WB. Hepatocyte paraffin 1: a monoclonal antibody that reacts with hepatocytes and can be used for differential diagnosis of hepatic tumors. Am J Pathol. 1993;143(4):1050–4.

    CAS  PubMed  PubMed Central  Google Scholar 

  107. Butler SL, Dong H, Cardona D, Jia M, Zheng R, Zhu H, et al. The antigen for Hep Par 1 antibody is the urea cycle enzyme carbamoyl phosphate synthetase 1. Lab Invest. 2008;88(1):78–88.

    Article  CAS  PubMed  Google Scholar 

  108. Fan Z, van de Rijn M, Montgomery K, Rouse RV. Hep par 1 antibody stain for the differential diagnosis of hepatocellular carcinoma: 676 tumors tested using tissue microarrays and conventional tissue sections. Mod Pathol. 2003;16(2):137–44.

    Article  PubMed  Google Scholar 

  109. Lugli A, Tornillo L, Mirlacher M, Bundi M, Sauter G, Terracciano LM. Hepatocyte paraffin 1 expression in human normal and neoplastic tissues: tissue microarray analysis on 3,940 tissue samples. Am J Clin Pathol. 2004;122(5):721–7.

    Article  CAS  PubMed  Google Scholar 

  110. Geramizadeh B, Boub R, Rahsaz M. Histologic differentiation of hepatocellular carcinoma from adenocarcinoma by a simple panel: evaluation of the pitfalls. Indian J Pathol Microbiol. 2007;50(3):507–10.

    PubMed  Google Scholar 

  111. Gokden M, Shinde A. Recent immunohistochemical markers in the differential diagnosis of primary and metastatic carcinomas of the liver. Diagn Cytopathol. 2005;33(3):166–72.

    Google Scholar 

  112. Varma V, Cohen C. Immunohistochemical and molecular markers in the diagnosis of hepatocellular carcinoma. Adv Anat Pathol. 2004;11(5):239–49.

    Article  CAS  PubMed  Google Scholar 

  113. Sang W, Zhang W, Cui W, Li X, Abulajiang G, Li Q. Arginase-1 is a more sensitive marker than HepPar-1 and AFP in differential diagnosis of hepatocellular carcinoma from nonhepatocellular carcinoma. Tumour Biol. 2015 May;36(5):3881–6.

    Google Scholar 

  114. Radwan NA, Ahmed NS. The diagnostic value of arginase-1 immunostaining in differentiating hepatocellular carcinoma from metastatic carcinoma and cholangiocarcinoma as compared to HepPar-1. Diagn Pathol. 2012;7(1):149.

    Google Scholar 

  115. Geramizadeh B, Seirfar N. Diagnostic Value of arginase-1 and glypican-3 in differential diagnosis of hepatocellular carcinoma, cholangiocarcinoma and metastatic carcinoma of liver. Hepat Mon. 2015;15(7):e30336.

    Google Scholar 

  116. Song HH, Filmus J. The role of glypicans in mammalian development. Biochim Biophys Acta. 2002;1573(3):241–6.

    Article  CAS  PubMed  Google Scholar 

  117. Luo J-H, Ren B, Keryanov S, Tseng GC, Rao UNM, Monga SP, et al. Transcriptomic and genomic analysis of human hepatocellular carcinomas and hepatoblastomas. Hepatology. 2006;44(4):1012–24.

    Google Scholar 

  118. Baumhoer D, Tornillo L, Stadlmann S, Roncalli M, Diamantis EK, Terracciano LM. Glypican 3 expression in human nonneoplastic, preneoplastic, and neoplastic tissues: a tissue microarray analysis of 4,387 tissue samples. Am J Clin Pathol. 2008;129(6):899–906.

    Article  PubMed  Google Scholar 

  119. Nakatsura T, Kageshita T, Ito S, Wakamatsu K, Monji M, Ikuta Y, et al. Identification of glypican-3 as a novel tumor marker for melanoma. Clin Cancer Res. 2004;10(19):6612–21.

    Article  CAS  PubMed  Google Scholar 

  120. Miyaaki H, Nakashima O, Kurogi M, Eguchi K, Kojiro M. Lens culinaris agglutinin-reactive alpha-fetoprotein and protein induced by vitamin K absence II are potential indicators of a poor prognosis: a histopathological study of surgically resected hepatocellular carcinoma. J Gastroenterol. 2007 Dec;42(12):962–8.

    Google Scholar 

  121. Okuda H, Nakanishi T, Takatsu K, Saito A, Hayashi N, Yamamoto M, et al. Clinicopathologic features of patients with hepatocellular carcinoma seropositive for alpha-fetoprotein-L3 and seronegative for des-gamma-carboxy prothrombin in comparison with those seropositive for des-gamma-carboxy prothrombin alone. J Gastroenterol Hepatol. 2002;17(7):772–8.

    Article  CAS  PubMed  Google Scholar 

  122. Li D, Satomura S. Biomarkers for hepatocellular carcinoma (HCC): an update. Adv Exp Med Biol. 2015;867:179–93 (Chapter 12).

    Google Scholar 

  123. Yao S, Zhang J, Chen H, Sheng Y, Zhang X, Liu Z, et al. Diagnostic value of immunohistochemical staining of GP73, GPC3, DCP, CD34, CD31, and reticulin staining in hepatocellular carcinoma. J Histochem Cytochem. 2013;61(9):639–48.

    Google Scholar 

  124. European association for the study of the liver, european organisation for research and treatment of cancer: EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol. 2012;908–43.

    Google Scholar 

  125. Pinyol R, Nault JC, Quetglas IM, Zucman Rossi J, Llovet JM. Molecular profiling of liver tumors: classification and clinical translation for decision making. Semin Liver Dis. 2014;34(4):363–75.

    Google Scholar 

  126. Lee J-S, Chu I-S, Heo J, Calvisi DF, Sun Z, Roskams T, et al. Classification and prediction of survival in hepatocellular carcinoma by gene expression profiling. Hepatology. 2004;40(3):667–76.

    Google Scholar 

  127. Villanueva A, Hoshida Y, Battiston C, Tovar V, Sia D, Alsinet C, et al. Combining clinical, pathology, and gene expression data to predict recurrence of hepatocellular carcinoma. Gastroenterology. 2011;140(5):1501–2.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  128. Nault JC, De Reyniès A, Villanueva A, Calderaro J, Rebouissou S, Couchy G, et al. A hepatocellular carcinoma 5-gene score associated with survival of patients after liver resection. Gastroenterology. 2013;145(1):176–87.

    Article  CAS  PubMed  Google Scholar 

  129. Goyal L, Muzumdar MD, Zhu AX. Targeting the HGF/c-MET pathway in hepatocellular carcinoma. Clin Cancer Res. 2013;19(9):2310–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  130. Wang Y, Li H, Liang Q, Liu B, Mei X, Ma Y. Combinatorial immunotherapy of sorafenib and blockade of programmed death-ligand 1 induces effective natural killer cell responses against hepatocellular carcinoma. Tumour Biol. 2015;36(3):1561–6.

    Google Scholar 

  131. Wang B-J, Bao J-J, Wang J-Z, Wang Y, Jiang M, Xing M-Y, et al. Immunostaining of PD-1/PD-Ls in liver tissues of patients with hepatitis and hepatocellular carcinoma. World J Gastroenterol. 2011;17(28):3322–9.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  132. Torbenson M. Review of the clinicopathologic features of fibrolamellar carcinoma. Adv Anat Pathol. 2007;14(3):217–23.

    Article  PubMed  Google Scholar 

  133. Berman MM, Libbey NP, Foster JH. Hepatocellular carcinoma. polygonal cell type with fibrous stroma—an atypical variant with a favorable prognosis. Cancer. 1980;46(6):1448–55.

    Article  CAS  PubMed  Google Scholar 

  134. El-Serag HB, Davila JA. Is fibrolamellar carcinoma different from hepatocellular carcinoma? A US population-based study. Hepatology. 2004;39(3):798–803.

    Google Scholar 

  135. Hoshino H, Katada N, Nishimura D, Imada J, Morita K, Yoshida N, et al. Case report: fibrolamellar hepatocellular carcinoma in a Japanese woman: a case report and review of Japanese cases. J Gastroenterol Hepatol. 1996;11(6):551–5.

    Article  CAS  PubMed  Google Scholar 

  136. Yoshimi F, Asato Y, Amemiya R, Itabashi M, Nakamura K. Fibrolamellar hepatocellular carcinoma in a Japanese man: report of a case. Surg Today. 2002;32(2):174–9.

    Article  PubMed  Google Scholar 

  137. Mansouri D, Van Nhieu JT, Couanet D, Terrier-Lacombe M-J, Brugières L, Cherqui D, et al. Fibrolamellar hepatocellular carcinoma: a case report with cytological features in a sixteen-year-old girl. Diagn Cytopathol. 2006;34(8):568–71.

    Google Scholar 

  138. Bilbao I, Vilallonga R, Allende E, Montero A, Quiroga S, Viladomiu L, et al. Krukenberg’s tumor as the first clinical manifestation of fibrolamellar hepatocarcinoma. Gastroenterol Hepatol. 2008;31(6):341–6.

    Article  PubMed  Google Scholar 

  139. Ichikawa T, Federle MP, Grazioli L, Marsh W. Fibrolamellar hepatocellular carcinoma: pre- and posttherapy evaluation with CT and MR imaging. Radiology. 2000;217(1):145–51.

    Article  CAS  PubMed  Google Scholar 

  140. Caballero T, Aneiros J, Lopez-Caballero J, Gomez-Morales M, Nogales F. Fibrolamellar hepatocellular carcinoma. An immunohistochemical and ultrastructural study. Histopathology. 1985;9(4):445–56.

    Article  CAS  PubMed  Google Scholar 

  141. An T, Ghatak N, Kastner R, Kay S, Lee HM. Hyaline globules and intracellular lumina in a hepatocellular carcinoma. Am J Clin Pathol. 1983;79(3):392–6.

    Article  CAS  PubMed  Google Scholar 

  142. Lefkowitch JH, Muschel R, Price JB, Marboe C, Braunhut S. Copper and copper-binding protein in fibrolamellar liver cell carcinoma. Cancer. 1983;51(1):97–100.

    Article  CAS  PubMed  Google Scholar 

  143. Tanaka K, Honna T, Kitano Y, Kuroda T, Morikawa N, Matsuda H, et al. Combined fibrolamellar carcinoma and cholangiocarcinoma exhibiting biphenotypic antigen expression: a case report. J Clin Pathol. 2005;58(8):884–7.

    Google Scholar 

  144. Seitz G, Zimmermann A, Friess H, Büchler MW. Adult-type hepatocellular carcinoma in the center of a fibrolamellar hepatocellular carcinoma. Hum Pathol. 2002;33(7):765–9.

    Article  PubMed  Google Scholar 

  145. Castro-Villabón D, Barrera-Herrera LE, Rodríguez-Urrego PA, Hudacko R, Vera A, Álvarez J, et al. Hepatocellular carcinoma with both fibrolamellar and classical components: an unusual morphological pattern. Case Rep Pathol. 2015;2015(2):609780–5.

    Google Scholar 

  146. Cheuk W, Chan JK. Clear cell variant of fibrolamellar carcinoma of the liver. Arch Pathol Lab Med. 2001;125(9):1235–8.

    CAS  PubMed  Google Scholar 

  147. Chagas AL, Kikuchi L, Herman P, Alencar RSSM, Tani CM, Diniz MA, et al. Clinical and pathological evaluation of fibrolamellar hepatocellular carcinoma: a single center study of 21 cases. Clinics. 2015;70(3):207–13.

    Article  PubMed  PubMed Central  Google Scholar 

  148. Nerlich AG, Majewski S, Hunzelmann N, Brenner RE, Wiebecke B, Müller PK, et al. Excessive collagen formation in fibrolamellar carcinoma of the liver: a morphological and biochemical study. Mod Pathol. 1992;5(5):580–5.

    CAS  PubMed  Google Scholar 

  149. Orsatti G, Hytiroglou P, Thung SN, Ishak KG, Paronetto F. Lamellar fibrosis in the fibrolamellar variant of hepatocellular carcinoma: a role for transforming growth factor beta. Liver. 1997;17(3):152–6.

    Article  CAS  PubMed  Google Scholar 

  150. Klein WM, Molmenti EP, Colombani PM, Grover DS, Schwarz KB, Boitnott J, et al. Primary liver carcinoma arising in people younger than 30 years. Am J Clin Pathol. 2005;124(4):512–8.

    Article  PubMed  Google Scholar 

  151. Van Eyken P, Sciot R, Brock P, Casteels-Van Daele M, Ramaekers FC, Desmet VJ. Abundant expression of cytokeratin 7 in fibrolamellar carcinoma of the liver. Histopathology. 1990;17(2):101–7.

    Article  PubMed  Google Scholar 

  152. Ross HM, Daniel HDJ, Vivekanandan P, Kannangai R, Yeh MM, Wu T-T, et al. Fibrolamellar carcinomas are positive for CD68. Mod Pathol. 2011;24(3):390–5.

    Article  CAS  PubMed  Google Scholar 

  153. Berman MA, Burnham JA, Sheahan DG. Fibrolamellar carcinoma of the liver: an immunohistochemical study of nineteen cases and a review of the literature. Hum Pathol. 1988;19(7):784–94.

    Article  CAS  PubMed  Google Scholar 

  154. Okano A, Hajiro K, Takakuwa H, Kobashi Y. Fibrolamellar carcinoma of the liver with a mixture of ordinary hepatocellular carcinoma: a case report. Am J Gastroenterol. 1998;93(7):1144–5.

    Article  CAS  PubMed  Google Scholar 

  155. Shafizadeh N, Ferrell LD, Kakar S. Utility and limitations of glypican-3 expression for the diagnosis of hepatocellular carcinoma at both ends of the differentiation spectrum. Mod Pathol. 2008;21(8):1011–8.

    Article  CAS  PubMed  Google Scholar 

  156. Honeyman JN, Simon EP, Robine N, Chiaroni-Clarke R, Darcy DG, Lim IIP, et al. Detection of a recurrent DNAJB1-PRKACA chimeric transcript in fibrolamellar hepatocellular carcinoma. Science. 2014;343(6174):1010–4.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  157. Cornella H, Alsinet C, Sayols S, Zhang Z, Hao K, Cabellos L, et al. Unique genomic profile of fibrolamellar hepatocellular carcinoma. Gastroenterology. 2015;148(4):806–10.

    Article  CAS  PubMed  Google Scholar 

  158. Simon EP, Freije CA, Farber BA, Lalazar G, Darcy DG, Honeyman JN, et al. Transcriptomic characterization of fibrolamellar hepatocellular carcinoma. Proc Natl Acad Sci USA. 2015;112(44):E5916–25.

    Google Scholar 

  159. Reid LM, Sethupathy P. The DNAJB1-PRKACA chimera: candidate biomarker and therapeutic target for fibrolamellar carcinomas. Hepatology. 2015;n/a–n/a.

    Google Scholar 

  160. Graham RP, Jin L, Knutson DL, Kloft-Nelson SM, Greipp PT, Waldburger N, et al. DNAJB1-PRKACA is specific for fibrolamellar carcinoma. Mod Pathol. 2015;28(6):822–9.

    Article  CAS  PubMed  Google Scholar 

  161. Hemming AW, Langer B, Sheiner P, Greig PD, Taylor BR. Aggressive surgical management of fibrolamellar hepatocellular carcinoma. J Gastrointest Surg. 1997;1(4):342–6.

    Article  CAS  PubMed  Google Scholar 

  162. Zografos GN, Palmer S, Papastratis G, Habib NA. Aggressive surgical management of fibrolamellar hepatocellular carcinoma in puberty. Eur J Surg Oncol. 1997;23(6):570–2.

    Article  CAS  PubMed  Google Scholar 

  163. Starzl TE, Iwatsuki S, Shaw BW, Nalesnik MA, Farhi DC, Van Thiel DH. Treatment of fibrolamellar hepatoma with partial or total hepatectomy and transplantation of the liver. Surg Gynecol Obstet. 1986;162(2):145–8.

    CAS  PubMed  PubMed Central  Google Scholar 

  164. Pinna AD, Iwatsuki S, Lee RG, Todo S, Madariaga JR, Marsh JW, et al. Treatment of fibrolamellar hepatoma with subtotal hepatectomy or transplantation. Hepatology. 1997;26(4):877–83.

    Google Scholar 

  165. Moreno-Luna LE, Arrieta O, García-Leiva J, Martínez B, Torre A, Uribe M, et al. Clinical and pathologic factors associated with survival in young adult patients with fibrolamellar hepatocarcinoma. 2005;5(1):142.

    Google Scholar 

  166. Stipa F, Yoon SS, Liau KH, Fong Y, Jarnagin WR, D’Angelica M, et al. Outcome of patients with fibrolamellar hepatocellular carcinoma. Cancer. 2006;106(6):1331–8.

    Google Scholar 

  167. Katzenstein HM, Krailo MD, Malogolowkin MH, Ortega JA, Qu W, Douglass EC, et al. Fibrolamellar hepatocellular carcinoma in children and adolescents. Cancer. 2003;97(8):2006–12.

    Google Scholar 

  168. Darcy DG, Malek MM, Kobos R, Klimstra DS, DeMatteo R, La Quaglia MP. Prognostic factors in fibrolamellar hepatocellular carcinoma in young people. J Pediatr Surg. 2015;50(1):153–6.

    Article  PubMed  Google Scholar 

  169. Orikasa H, Ohyama R, Tsuka N, Eyden BP, Yamazaki K. Lipid-rich clear-cell hepatocellular carcinoma arising in non-alcoholic steatohepatitis in a patient with diabetes mellitus. J Submicrosc Cytol Pathol. 2001;33(1–2):195–200.

    CAS  PubMed  Google Scholar 

  170. Takahashi A, Saito H, Kanno Y, Abe K, Yokokawa J, Irisawa A, et al. Case of clear-cell hepatocellular carcinoma that developed in the normal liver of a middle-aged woman. World J Gastroenterol. 2008;14(1):129–31.

    Google Scholar 

  171. Liu Z, Ma W, Li H, Li Q. Clinicopathological and prognostic features of primary clear cell carcinoma of the liver. Hepatol Res. 2008;38(3):291–9.

    Article  PubMed  Google Scholar 

  172. Sasaki K, Okuda S, Takahashi M, Sasaki M. Hepatic clear cell carcinoma associated with hypoglycemia and hypercholesterolemia. Cancer. 1981;47(4):820–2.

    Article  CAS  PubMed  Google Scholar 

  173. Zen Y, Vara R, Portmann B, Hadzic N. Childhood hepatocellular carcinoma: a clinicopathological study of 12 cases with special reference to EpCAM. Histopathology. 2014;64(5):671–82.

    Article  PubMed  Google Scholar 

  174. Murakata LA, Ishak KG, Nzeako UC. Clear cell carcinoma of the liver: a comparative immunohistochemical study with renal clear cell carcinoma. Mod Pathol. 2000;13(8):874–81.

    Article  CAS  PubMed  Google Scholar 

  175. Zhang W, Wang Q, Jiang Y-X, Lu Q, Yu W-J, Liu Y, et al. Simultaneous double primary clear cell carcinomas of liver and kidney: a case report and review of literature. Int J Clin Exp Pathol. 2015;8(1):995–9.

    Google Scholar 

  176. Sugiyama T, Tajiri T, Hiraiwa S, Inomoto C, Kajiwara H, Kojima S, et al. Hepatic adrenal rest tumor: diagnostic pitfall and proposed algorithms to prevent misdiagnosis as lipid-rich hepatocellular carcinoma. Pathol Int. 2015;65(2):95–9.

    Article  CAS  PubMed  Google Scholar 

  177. Emile JF, Lemoine A, Azoulay D, Debuire B, Bismuth H, Reynès M. Histological, genomic and clinical heterogeneity of clear cell hepatocellular carcinoma. Histopathology. 2001;38(3):225–31.

    Article  CAS  PubMed  Google Scholar 

  178. Lao X-M, Zhang Y-Q, Jin X, Lin X-J, Guo R-P, Li G-H, et al. Primary clear cell carcinoma of liver–clinicopathologic features and surgical results of 18 cases. Hepatogastroenterology. 2006;53(67):128–32.

    PubMed  Google Scholar 

  179. Clayton EF, Malik S, Bonnel A, Mu Y, Olthoff K, Shaked A, et al. Liver transplantation and cirrhotomimetic hepatocellular carcinoma: classification and outcomes. Liver Transpl. 2014;20(7):765–74.

    Article  PubMed  PubMed Central  Google Scholar 

  180. Jeon S-W, Lee M-K, Lee Y-D, Seo H-E, Cho C-M, Tak W-Y, et al. Clear cell hepatocellular carcinoma with spontaneous regression of primary and metastatic lesions. Korean J Intern Med. 2005;20(3):268–73.

    Article  PubMed  PubMed Central  Google Scholar 

  181. Orsatti G, Arnold MM, Paronetto F. DNA image cytometric analysis of primary clear cell carcinoma of the liver. Arch Pathol Lab Med. 1994;118(12):1226–9.

    CAS  PubMed  Google Scholar 

  182. Okuda K. Hepatocellular carcinoma: clinicopathological aspects. J Gastroenterol Hepatol. 1997;12(9–10):S314–8.

    Article  CAS  PubMed  Google Scholar 

  183. Albar JP, De Miguel F, Esbrit P, Miranda R, Fernandez-Flores A, Sarasa JL. Immunohistochemical detection of parathyroid hormone-related protein in a rare variant of hepatic neoplasm (sclerosing hepatic carcinoma). Hum Pathol. 1996;27(7):728–31.

    Article  CAS  PubMed  Google Scholar 

  184. Kim SH, Lim HK, Lee WJ, Choi D, Park C-K. Scirrhous hepatocellular carcinoma: comparison with usual hepatocellular carcinoma based on CT-pathologic features and long-term results after curative resection. Eur J Radiol. 2009;69(1):123–30.

    Article  PubMed  Google Scholar 

  185. Fujii T, Zen Y, Nakanuma Y. Minute scirrhous hepatocellular carcinomas undergoing different carcinogenetic processes. Pathol Int. 2007;57(7):443–8.

    Article  PubMed  Google Scholar 

  186. Kurogi M, Nakashima O, Miyaaki H, Fujimoto M, Kojiro M. Clinicopathological study of scirrhous hepatocellular carcinoma. J Gastroenterol Hepatol. 2006;21(9):1470–7.

    PubMed  Google Scholar 

  187. Krings G, Ramachandran R, Jain D, Wu T-T, Yeh MM, Torbenson M, et al. Immunohistochemical pitfalls and the importance of glypican 3 and arginase in the diagnosis of scirrhous hepatocellular carcinoma. Mod Pathol. 2013;26(6):782–91.

    Article  CAS  PubMed  Google Scholar 

  188. Okamura N, Yoshida M, Shibuya A, Sugiura H, Okayasu I, Ohbu M. Cellular and stromal characteristics in the scirrhous hepatocellular carcinoma: comparison with hepatocellular carcinomas and intrahepatic cholangiocarcinomas. Pathol Int. 2005;55(11):724–31.

    Google Scholar 

  189. Kim H, Park YN. Hepatocellular carcinomas expressing “stemness-”related markers: clinicopathological characteristics. Dig Dis. 2014;32(6):778–85.

    Google Scholar 

  190. Lee JH, Choi MS, Gwak GY, Lee JH, Koh KC, Paik SW, et al. Clinicopathologic characteristics and long-term prognosis of scirrhous hepatocellular carcinoma. Dig Dis Sci. 2012;57(6):1698–707.

    Google Scholar 

  191. Kassahun WT, Hauss J. Management of combined hepatocellular and cholangiocarcinoma. Int J Clin Pract. 2008;62(8):1271–8.

    Google Scholar 

  192. Zhou Y-M, Zhang X-F, Wu L-P, Sui C-J, Yang J-M. Risk factors for combined hepatocellular-cholangiocarcinoma: a hospital-based case-control study. World J Gastroenterol. 2014;20(35):12615–20.

    Article  PubMed  PubMed Central  Google Scholar 

  193. Wachtel MS, Zhang Y, Xu T, Chiriva-Internati M, Frezza EE. Combined hepatocellular cholangiocarcinomas; analysis of a large database. Clin Med Pathol. 2008;1:43–7.

    Google Scholar 

  194. O’Connor K, Walsh JC, Schaeffer DF. Combined hepatocellular-cholangiocarcinoma (cHCC-CC): a distinct entity. Ann Hepatol. 2014;13(3):317–22.

    PubMed  Google Scholar 

  195. Kim SH, Park YN, Lim JH, Choi GH, Choi JS, Kim KS. Characteristics of combined hepatocelluar-cholangiocarcinoma and comparison with intrahepatic cholangiocarcinoma. Eur J Surg Oncol. 2014;40(8):976–81.

    Article  CAS  PubMed  Google Scholar 

  196. Garancini M, Goffredo P, Pagni F, Romano F, Roman S, Sosa JA, Giardini V. Combined hepatocellular-cholangiocarcinoma: a population-level analysis of an uncommon primary liver tumor. Liver Transplant 2014;20(8):952–9.

    Google Scholar 

  197. Wu C, Bai D-S, Jiang G-Q, Jin S-J. Synchronous double cancers of primary hepatocellular carcinoma and intrahepatic cholangiocarcinoma: a case report and review of the literature. World J Surg Oncol. 2014;12(1):337.

    Google Scholar 

  198. Geramizadeh B, Gity R, Bahraini A, Malek-Hosseini SA. Synchronous hepatocellular carcinoma and cholangiocarcinoma in a patient transplanted for cryptogenic cirrhosis. Int J Organ Transplant Med. 2014;5(3):125–8.

    Google Scholar 

  199. Zhang F, Chen X-P, Zhang W, Dong H-H, Xiang S, Zhang W-G, et al. Combined hepatocellular cholangiocarcinoma originating from hepatic progenitor cells: immunohistochemical and double-fluorescence immunostaining evidence. Histopathology. 2008;52(2):224–32.

    Google Scholar 

  200. Imai Y, Oda H, Arai M, Shimizu S, Nakatsuru Y, Inoue T, et al. Mutational analysis of the p53 and K-ras genes and allelotype study of the Rb-1 gene for investigating the pathogenesis of combined hapatocellular-cholangiocellular carcinomas. Jpn J Cancer Res. 1996;87(10):1056–62.

    Article  CAS  PubMed  Google Scholar 

  201. Yano H, Iemura A, Haramaki M, Momosaki S, Ogasawara S, Higaki K, et al. A human combined hepatocellular and cholangiocarcinoma cell line (KMCH-2) that shows the features of hepatocellular carcinoma or cholangiocarcinoma under different growth conditions. J Hepatol. 1996;24(4):413–22.

    Article  CAS  PubMed  Google Scholar 

  202. Gil-Benso R, Martinez-Lorente A, Pellin-Perez A, Navarro-Fos S, Gregori-Romero MA, Carda C, et al. Characterization of a new rat cell line established from 2′AAF-induced combined hepatocellular cholangiocellular carcinoma. In Vitro Cell Dev Biol Anim. 2001;37(1):17–25.

    Google Scholar 

  203. Papotti M, Sambataro D, Marchesa P, Negro F. A combined hepatocellular/cholangiocellular carcinoma with sarcomatoid features. Liver. 1997;17(1):47–52.

    Article  CAS  PubMed  Google Scholar 

  204. Shafizadeh N, Kakar S. Hepatocellular carcinoma: histologic subtypes. Surg Pathol. 2013;367–84.

    Google Scholar 

  205. Akasofu M, Kawahara E, Kaji K, Nakanishi I. Sarcomatoid hepatocellular-carcinoma showing rhabdomyoblastic differentiation in the adult cirrhotic liver. Virchows Arch. 1999;434(6):511–5.

    Article  CAS  PubMed  Google Scholar 

  206. Fu Y, Kobayashi S, Kushida Y, Saoo K, Haba R, Mori S, et al. Sarcomatoid hepatocellular carcinoma with chondroid variant: case report with immunohistochemical findings. Pathol Int. 2000;50(11):919–22.

    Article  CAS  PubMed  Google Scholar 

  207. Haratake J, Horie A. An immunohistochemical study of sarcomatoid liver carcinomas. Cancer. 1991;68(1):93–7.

    Article  CAS  PubMed  Google Scholar 

  208. Sasaki A, Yokoyama S, Nakayama I, Nakashima K, Kim YI, Kitano S. Sarcomatoid hepatocellular carcinoma with osteoclast-like giant cells: case report and immunohistochemical observations. Pathol Int. 1997;47(5):318–24.

    Article  CAS  PubMed  Google Scholar 

  209. Dahm HH. Immunohistochemical evaluation of a sarcomatoid hepatocellular carcinoma with osteoclastlike giant cells. Diagn Pathol. 2015;10(1):40.

    Google Scholar 

  210. Boonsakan P, Thangnapakorn O, Tapaneeyakorn J, Kositchaiwat S, Bunyaratvej S. Case report combined hepatocellular and cholangiocarcinoma with sarcomatous transformation. J Med Assoc Thai. 2007;90(3):574–80.

    PubMed  Google Scholar 

  211. Chin S, Kim Z. Sarcomatoid combined hepatocellular-cholangiocarcinoma: a case report and review of literature. Int J Clin Exp Pathol. 2014;7(11):8290–4.

    Google Scholar 

  212. Kojiro M, Sugihara S, Kakizoe S, Nakashima O, Kiyomatsu K. Hepatocellular carcinoma with sarcomatous change: a special reference to the relationship with anticancer therapy. Cancer Chemother Pharmacol. 1989;23(Suppl):S4–8.

    Article  PubMed  Google Scholar 

  213. Chan AWH, Tong JHM, Pan Y, Chan SL, Wong GLH, Wong VWS, et al. Lymphoepithelioma-like hepatocellular carcinoma: an uncommon variant of hepatocellular carcinoma with favorable outcome. Am J Surg Pathol. 2015;39(3):304–12.

    Article  PubMed  Google Scholar 

  214. Patel KR, Liu T-C, Vaccharajani N, Chapman WC, Brunt EM. Characterization of inflammatory (lymphoepithelioma-like) hepatocellular carcinoma: a study of 8 cases. Arch Pathol Lab Med. 2014;138(9):1193–202.

    Article  PubMed  Google Scholar 

  215. Quist E, Talmon G, Hartman C, Wisecarver J. Medullary-like hepatocellular carcinoma: an unusual histologic variant. Am J Clin Pathol. 2014;142(5):670–4.

    Article  PubMed  Google Scholar 

  216. Darbari A, Sabin KM, Shapiro CN, Schwarz KB. Epidemiology of primary hepatic malignancies in US children. Hepatology. 2003;38(3):560–6.

    Google Scholar 

  217. Yoshida R, Ogata T, Masawa N, Nagai T. Hepatoblastoma in a noonan syndrome patient with a PTPN11 mutation. Pediatr Blood Cancer. 2008;50(6):1274–6.

    Google Scholar 

  218. Giardiello FM, Offerhaus GJ, Krush AJ, Booker SV, Tersmette AC, Mulder JW, et al. Risk of hepatoblastoma in familial adenomatous polyposis. J Pediatr. 1991;119(5):766–8.

    Article  CAS  PubMed  Google Scholar 

  219. Ishak KG, Glunz PR. Hepatoblastoma and hepatocarcinoma in infancy and childhood: report of 47 cases. Cancer. 1967;20(3):396–422.

    Article  CAS  PubMed  Google Scholar 

  220. Ito E, Sato Y, Kawauchi K, Munakata H, Kamata Y, Yodono H, et al. Type 1a glycogen storage disease with hepatoblastoma in siblings. Cancer. 1987;59(10):1776–80.

    Article  CAS  PubMed  Google Scholar 

  221. Lynch HT, Thorson AG, McComb RD, Franklin BA, Tinley ST, Lynch JF. Familial adenomatous polyposis and extracolonic cancer. Dig Dis Sci. 2001;46(11):2325–32.

    Article  CAS  PubMed  Google Scholar 

  222. Weinberg AG, Finegold MJ. Primary hepatic tumors of childhood. Hum Pathol. 1983;14(6):512–37.

    Article  CAS  PubMed  Google Scholar 

  223. Lopez-Terrada D, Alaggio R, de Dávila MT, Czauderna P, Hiyama E, Katzenstein H, et al. Towards an international pediatric liver tumor consensus classification. In: Proceedings of the Los Angeles COG liver tumors symposium. 2014. p. 472–91.

    Google Scholar 

  224. Czauderna P, Lopez-Terrada D, Hiyama E, Häberle B, Malogolowkin MH, Meyers RL. Hepatoblastoma state of the art: pathology, genetics, risk stratification, and chemotherapy. Curr Opin Pediatr. 2014;26(1):19–28.

    Article  CAS  PubMed  Google Scholar 

  225. Malogolowkin MH, Katzenstein HM, Meyers RL, Krailo MD, Rowland JM, Haas J, et al. Complete surgical resection is curative for children with hepatoblastoma with pure fetal histology: a report from the children’s oncology group. J Clin Oncol. 2011;29(24):3301–6.

    Article  PubMed  PubMed Central  Google Scholar 

  226. Agaimy A. The expanding family of SMARCB1(INI1)-deficient neoplasia: implications of phenotypic, biological, and molecular heterogeneity. Adv Anat Pathol. 2014;21(6):394–410.

    Article  CAS  PubMed  Google Scholar 

  227. Beckwith JB, Palmer NF. Histopathology and prognosis of wilms tumors: results from the first national wilms’ tumor study. Cancer. 1978;41(5):1937–48.

    Article  CAS  PubMed  Google Scholar 

  228. Zhou S, Gomulia E, Mascarenhas L, Wang L. Is INI1-retained small cell undifferentiated histology in hepatoblastoma unfavorable? Hum Pathol. 2015;46(4):620–4.

    Article  CAS  PubMed  Google Scholar 

  229. Eichenmüller M, Trippel F, Kreuder M, Beck A, Schwarzmayr T, Häberle B, et al. The genomic landscape of hepatoblastoma and their progenies with HCC-like features. J Hepatol. 2014;61(6):1312–20.

    Article  PubMed  CAS  Google Scholar 

  230. Curia MC, Zuckermann M, De Lellis L, Catalano T, Lattanzio R, Aceto G, et al. Sporadic childhood hepatoblastomas show activation of beta-catenin, mismatch repair defects and p53 mutations. Mod Pathol. 2008;21(1):7–14.

    Article  CAS  PubMed  Google Scholar 

  231. Yamaoka H, Ohtsu K, Sueda T, Yokoyama T, Hiyama E. Diagnostic and prognostic impact of beta-catenin alterations in pediatric liver tumors. Oncol Rep. 2006;15(3):551–6.

    CAS  PubMed  Google Scholar 

  232. Ueda Y, Hiyama E, Kamimatsuse A, Kamei N, Ogura K, Sueda T. Wnt signaling and telomerase activation of hepatoblastoma: correlation with chemosensitivity and surgical resectability. J Pediatr Surg. 2011;46(12):2221–7.

    Article  PubMed  Google Scholar 

  233. Armengol C, Cairo S, Fabre M, Buendia MA. Wnt signaling and hepatocarcinogenesis: the hepatoblastoma model. Int J Biochem Cell Biol. 2011;43(2):265–70.

    Article  CAS  PubMed  Google Scholar 

  234. Cairo S, Armengol C, De Reyniès A, Wei Y, Thomas E, Renard C-A, et al. Hepatic stem-like phenotype and interplay of Wnt/beta-catenin and Myc signaling in aggressive childhood liver cancer. Cancer Cell. 2008;14(6):471–84.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Transplantation and Hepatic Pathology, University of Pittsburgh Medical Center, E733 Montefiore Hospital, Pittsburgh, PA, 15213, USA

    Michael A. Nalesnik

Authors
  1. Michael A. Nalesnik
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Michael A. Nalesnik .

Editor information

Editors and Affiliations

  1. Dokuz Eylul University, Izmir Biomedicine and Genome Center Dokuz Eylul University, Izmir, Izmir, Turkey

    Brian I. Carr

Rights and permissions

Reprints and permissions

Copyright information

© 2016 Springer International Publishing Switzerland

About this chapter

Cite this chapter

Nalesnik, M.A. (2016). Aspects of Hepatocellular Tumor Pathology. In: Carr, B. (eds) Hepatocellular Carcinoma. Current Clinical Oncology. Springer, Cham. https://doi.org/10.1007/978-3-319-34214-6_20

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-34214-6_20

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-34212-2

  • Online ISBN: 978-3-319-34214-6

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation